Verastem (VSTM)

[stockguard]

VSTM 05/10/19 07:46am Verastem analyst commentary at BTIG Verastem price target lowered to $8 from $17 at BTIG. BTIG analyst Robert Hazlett lowers his price target on Verastem to $8 after its Q1 results featured a more modest 2019 sales guidance for Copiktra at $10M-$12M - below his estimate of $50M. The analyst contends that the guidance suggests overcoming the challenges of Copiktra launch will take longer than anticipated, adding that he is also removing the possibility of M&A from his model. Hazlett keeps his Buy rating on the stock however and still believes in Copiktra's potential to "materially disrupt the tumor microenvironment.